Fig. 7

Addition of ATO to Gilteritinib activates IRE1a-JNK pathway to induce apoptosis. a–d MV4-11 and MOLM13 cells were treated with Gilteritinib (5 nM) for 48 h and protein levels of FLT3 were determined by western blot. Data are shown as the mean ± SD. *P < 0.05, ***P < 0.001. e, f MV4-11 cells were treated with Gilteritinib (2.5 nM or 5 nM) for 48 h and protein levels of GRP94, PERK, ATF6 and IRE1a were determined by western blot. Data are shown as the mean ± SD. *P < 0.05, **P < 0.01. g, h MV4-11 cells were treated with Gilteritinib (2.5 nM or 5 nM) for 48 h and protein levels of JNK and P-JNK were determined by western blot. Data are shown as the mean ± SD. **P < 0.01. i, j MV4-11 and MOLM13 cells were treated with Gilteritinib (2.5 nM) and/or ATO (0.5 µM) for 48 h and protein levels of IRE1a, JNK and P-JNK were determined by western blot. Data are shown as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001. P-JNK phosphorylated-JNK